rowid,id,name,description,createdAt,updatedAt,datasetId,additionalInfo,link,dataPublishedBy
13852,15410,"Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nAntiretroviral therapy coverage among people with advanced HIV infection (%)\n\nName abbreviated\nAntiretroviral therapy coverage among people with advanced HIV infection (%)\n\nData Type Representation\nPercent\n\nTopic\nHealth service coverage\n\nISO Health Indicators Framework\n\n \n\nRationale\nAs the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with advanced HIV infection.\n\nDefinition\nThe percentage of adults and children with advanced HIV infection currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocols (or WHO/UNAIDS standards) among the estimated number of adults and children with advanced HIV infection.\n \nNumerator: Number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period\nDenominator: Estimated number of adults and children with advanced HIV infection\n\nAssociated terms\nAntiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO/UNAIDS standards). ARV regimen prescribed for post exposure prophylaxis are excluded.\n\nAssociated terms\nHuman Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.\n\nPreferred data sources\nFacility reporting system\n\nPreferred data sources\nAdministrative reporting system\n\nPreferred data sources\nSurveillance systems\n\nOther possible data sources\n\n \n\nMethod of measurement\nNumerator\nThe numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Antiretroviral therapy taken only for the purpose of prevention of mother-to-child transmission and post-exposure prophylaxis are not included in this indicator. HIV-infected pregnant women who are eligible for antiretroviral therapy and on antiretroviral therapy for their own treatment are included in this indicator.\nThe number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy can be obtained through data collected from facility-based antiretroviral therapy registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving antiretroviral therapy in the private sector and public sector should be included in the numerator where data are available.\n\nDenominator\nThe denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) antiretroviral therapy. This estimation must take into consideration a variety of factors including, but not limited to, the current numbers of people with HIV, the current number of patients on antiretroviral therapy, and the natural history of HIV from infection to enrolment on antiretroviral therapy. A standard modelling method is recommended. The Estimation and Projection Package (EPP)* and Spectrum*, softwares have been developed by the UNAIDS/WHO Reference Group on Estimates, Models and Projections. Need or eligibility for antiretroviral therapy should follow the WHO definitions for the diagnosis of advanced HIV (including AIDS) for adults and children.\n\n(UNAIDS, 2009)\n\nMethod of estimation\nWHO, UNAIDS and UNICEF are responsible for reporting data for this indicator at the international level, and have been compiling country specific data since 2003.\n \nThe data from countries are collected through three international monitoring and reporting processes.\n1. Health sector response to HIV/AIDS (WHO/UNAIDS/UNICEF)\n3. UNGASS Declaration of Commitment on HIV/AIDS (UNAIDS)\nBoth processes are linked through common indicators and a harmonized timeline for reporting. \n \nEstimating the numerator\nData for the calculation of the numerator are compiled from the most recent reports received by WHO and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services. \n \nEstimating the denominator\nThe number of people who need antiretroviral therapy in a country is estimated using statistical modelling methods. \n\nIn response to the emergence of new scientific evidence, in December 2009 WHO updated its antiretroviral therapy guidelines for adults and adolescents. According to the new guidelines, which were developed in consultation with multiple technical and implementing partners, all adolescents and adults, including pregnant women, with HIV infection and a CD4 count at or below 350 cells/mm3 should be started on antiretroviral therapy, regardless of whether or not they have clinical symptoms. Those with severe or advanced clinical disease (WHO clinical stage 3 or 4) should start antiretroviral therapy irrespective of CD4 cell count. \n\nIn order to compare the impact of the new guildelines, both sets of needs for the year 2009 are included, i.e. estimated needs estimated based on a threshold for initiation of antiretroviral therapy with < 200 cells/mm3 (old guidelines) as well as < 350 cells/mm3 (new guidelines).\n \nEstimating antiretroviral therapy coverage\nThe estimates of antiretroviral therapy coverage presented here are calculated by dividing the estimated number of people receiving antiretroviral therapy as of December by the number of people estimated to need treatment in same year (based on UNAIDS/WHO methods). \n\nPredominant type of statistics: predicted\n \n\nM&E Framework\nOutcome\n\nMethod of estimation of global and regional aggregates\nRegional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people needing antiretroviral therapy. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no need numbers have been established for these countries. Aggregated coverage percentages are based solely on low- and middle-income countries.\n\nDisaggregation\nSex\n\nDisaggregation\nAge\n\nDisaggregation\nProvider type (public/private)\n\nUnit of Measure\nN/A\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\n\n \n\nLimitations\nEstimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.\nTo analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of treatment need. Specialized software is used to generate uncertainty ranges around estimates for antiretroviral therapy need. Depending on the quality of surveillance data, the ranges for some countries can be large.\n\nLinks\nHIV/AIDS Data and Statistics (WHO)\n\nLinks\nMethods and assumptions for HIV estimates (UNAIDS)\n\nLinks\n2008 Report on the Global AIDS epidemics (UNAIDS, 2008)\n\nLinks\nGuidelines on Construction of Core Indicators: 2010 Reporting (UNAIDS, 2009)\n\nLinks\nTools for collecting data on the health sector response to HIV/AIDS in 2010 (WHO, 2010)\n\nLinks\n in Current Opinion in HIV and AIDS: Vol.5 Issue 1 p 97–102)\n\nLinks\nTowards universal access - Scaling up priority HIV/AIDS interventions in the health sector (WHO/UNAIDS/UNICEF, 2010)\n\nComments\nThis indicator permits monitoring trends in coverage but does not attempt to distinguish between different forms of antiretroviral therapy or to measure the cost, quality or effectiveness of treatment provided. These will each vary within and between countries and are liable to change over time.\n\nThe degree of utilization of antiretroviral therapy will depend on factors such as cost relative to local incomes, service delivery infrastructure and quality, availability and uptake of voluntary counseling and testing services, and perceptions of effectiveness and possible side effects of treatment.\n(UNAIDS, 2009)\n\nLatest country specific coverage for 2008 were not published as treatment guidelines have been revised, and the effects on treatment need for adults are currently being assessed.\n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:44,2018-03-23 12:44:44,2694,"Indicator name
Antiretroviral therapy coverage among people with advanced HIV infection (%)
Name abbreviated
Antiretroviral therapy coverage among people with advanced HIV infection (%)
Data Type Representation
Percent
Topic
Health service coverage
ISO Health Indicators Framework
Rationale
As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with advanced HIV infection.
Definition
The percentage of adults and children with advanced HIV infection currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocols (or WHO/UNAIDS standards) among the estimated number of adults and children with advanced HIV infection.
Numerator: Number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period
Denominator: Estimated number of adults and children with advanced HIV infection
Associated terms
Antiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO/UNAIDS standards). ARV regimen prescribed for post exposure prophylaxis are excluded.
Associated terms
Human Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.
Preferred data sources
Facility reporting system
Preferred data sources
Administrative reporting system
Preferred data sources
Surveillance systems
Other possible data sources
Method of measurement
Numerator
The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Antiretroviral therapy taken only for the purpose of prevention of mother-to-child transmission and post-exposure prophylaxis are not included in this indicator. HIV-infected pregnant women who are eligible for antiretroviral therapy and on antiretroviral therapy for their own treatment are included in this indicator.
The number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy can be obtained through data collected from facility-based antiretroviral therapy registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving antiretroviral therapy in the private sector and public sector should be included in the numerator where data are available.
Denominator
The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) antiretroviral therapy. This estimation must take into consideration a variety of factors including, but not limited to, the current numbers of people with HIV, the current number of patients on antiretroviral therapy, and the natural history of HIV from infection to enrolment on antiretroviral therapy. A standard modelling method is recommended. The Estimation and Projection Package (EPP)* and Spectrum*, softwares have been developed by the UNAIDS/WHO Reference Group on Estimates, Models and Projections. Need or eligibility for antiretroviral therapy should follow the WHO definitions for the diagnosis of advanced HIV (including AIDS) for adults and children.
(UNAIDS, 2009)
Method of estimation
WHO, UNAIDS and UNICEF are responsible for reporting data for this indicator at the international level, and have been compiling country specific data since 2003.
The data from countries are collected through three international monitoring and reporting processes.
1. Health sector response to HIV/AIDS (WHO/UNAIDS/UNICEF)
3. UNGASS Declaration of Commitment on HIV/AIDS (UNAIDS)
Both processes are linked through common indicators and a harmonized timeline for reporting.
Estimating the numerator
Data for the calculation of the numerator are compiled from the most recent reports received by WHO and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services.
Estimating the denominator
The number of people who need antiretroviral therapy in a country is estimated using statistical modelling methods.
In response to the emergence of new scientific evidence, in December 2009 WHO updated its antiretroviral therapy guidelines for adults and adolescents. According to the new guidelines, which were developed in consultation with multiple technical and implementing partners, all adolescents and adults, including pregnant women, with HIV infection and a CD4 count at or below 350 cells/mm3 should be started on antiretroviral therapy, regardless of whether or not they have clinical symptoms. Those with severe or advanced clinical disease (WHO clinical stage 3 or 4) should start antiretroviral therapy irrespective of CD4 cell count.
In order to compare the impact of the new guildelines, both sets of needs for the year 2009 are included, i.e. estimated needs estimated based on a threshold for initiation of antiretroviral therapy with < 200 cells/mm3 (old guidelines) as well as < 350 cells/mm3 (new guidelines).
Estimating antiretroviral therapy coverage
The estimates of antiretroviral therapy coverage presented here are calculated by dividing the estimated number of people receiving antiretroviral therapy as of December by the number of people estimated to need treatment in same year (based on UNAIDS/WHO methods).
Predominant type of statistics: predicted
M&E Framework
Outcome
Method of estimation of global and regional aggregates
Regional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people needing antiretroviral therapy. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no need numbers have been established for these countries. Aggregated coverage percentages are based solely on low- and middle-income countries.
Disaggregation
Sex
Disaggregation
Age
Disaggregation
Provider type (public/private)
Unit of Measure
N/A
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Limitations
Estimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.
To analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of treatment need. Specialized software is used to generate uncertainty ranges around estimates for antiretroviral therapy need. Depending on the quality of surveillance data, the ranges for some countries can be large.
Links
HIV/AIDS Data and Statistics (WHO)
Links
Methods and assumptions for HIV estimates (UNAIDS)
Links
2008 Report on the Global AIDS epidemics (UNAIDS, 2008)
Links
Guidelines on Construction of Core Indicators: 2010 Reporting (UNAIDS, 2009)
Links
Tools for collecting data on the health sector response to HIV/AIDS in 2010 (WHO, 2010)
Links
in Current Opinion in HIV and AIDS: Vol.5 Issue 1 p 97–102)
Links
Towards universal access - Scaling up priority HIV/AIDS interventions in the health sector (WHO/UNAIDS/UNICEF, 2010)
Comments
This indicator permits monitoring trends in coverage but does not attempt to distinguish between different forms of antiretroviral therapy or to measure the cost, quality or effectiveness of treatment provided. These will each vary within and between countries and are liable to change over time.
The degree of utilization of antiretroviral therapy will depend on factors such as cost relative to local incomes, service delivery infrastructure and quality, availability and uptake of voluntary counseling and testing services, and perceptions of effectiveness and possible side effects of treatment.
(UNAIDS, 2009)
Latest country specific coverage for 2008 were not published as treatment guidelines have been revised, and the effects on treatment need for adults are currently being assessed.
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13834,15392,Estimated antiretroviral therapy coverage among people living with HIV (%),"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated antiretroviral therapy coverage among people living with HIV (%)\n\nName abbreviated\nART coverage among people living with HIV (%)\n\nData Type Representation\nPercent\n\nTopic\nHealth service coverage\n\nISO Health Indicators Framework\n\n \n\nRationale\nAntiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with HIV infection. As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Over recent years WHO has issued various updates in the ARV guidelines. Under the 2013 WHO consolidated guidelines, roughly 85% people living with HIV would be eligible for treatment in 2013. For reasons of comparibility across countries and over time in the context of changing recommendations, this indicator relates to the number of people receiving ART as of proportion of the overall estimated number of people living with HIV. The ranges around the levels of people living with HIV who received ART are based on the uncertainty bounds around the estimates of people living with HIV.\n\nDefinition\nPercentage of people living with HIV currently receiving ART among the estimated number of adults and children living with HIV. Numerator: Number of adults and children who are currently receiving ART at the end of the reporting period. Denominator: Estimated number of adults and children living with HIV. \n\t\n\nAssociated terms\nAntiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO standards). ARV regimen prescribed for post exposure prophylaxis are excluded.\n\nAssociated terms\nHuman Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.\n\nPreferred data sources\nFacility reporting system\n\nOther possible data sources\nSentinel surveillance sites\n\nOther possible data sources\nPopulation-based surveys\n\nMethod of measurement\nNumerator: The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Data can be collected from facility-based ART registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving ART in the private sector and public sector should be included in the numerator where data are available.\n\tDenominator: The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) ART. This estimation must take into consideration a variety of factors, including, but not limited to, the current number of people with HIV, the current number of patients on ART and the natural history of HIV from infection to enrolment on ART. A standard modelling HIV estimation method, such as in the Spectrum model, is recommended.\n\t\n\nMethod of estimation\nModelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of people living with HIV and national programme records are used to determine the number receiving treatment. UNAIDS supports most countries to produce estimates of the number of people living with HIV annually using Spectrum. \n\nM&E Framework\nOutcome\n\nMethod of estimation of global and regional aggregates\nRegional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people living with HIV. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no estimates have been established for most high-income countries. Aggregated coverage percentages are based solely on low- and middle-income countries.\n\nDisaggregation\nAge: 1. Minimum for paper-based (routine): less than 15, 15+; 2. Annual data extraction of disaggregated data if not reported routinely: less than 5, 5–9, 10–14, 15–19, 20–24, 25–49, 50+; 3. Electronic system: 5-year age groups\n\nDisaggregation\nSex\n\nDisaggregation\nGeographic location\n\nDisaggregation\nKey populations (men who have sex with men, sex workers, people who inject drugs, transgender people, prisoners)\n\t\n\nDisaggregation\nProvider type (public/private)\n\nDisaggregation\nRegimen type (e.g. first line, second line)\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\nAnnual\n\nLimitations\nEstimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.\n\tTo analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of people living with HIV. Specialized software is used to generate uncertainty ranges around estimates. Depending on the quality of surveillance data, the ranges for some countries can be large.\n\t\n\nLinks\nConsolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015).\n\t\n\nLinks\nFramework of actions for the follow-up to the Programme of Action of the International Conference on Population and Development beyond 2014. Report of the Secretary-General. New York (NY): United Nations; 2014 (accessed 19 August 2014).\n\t\n\nLinks\nGlobal AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016.\n\nLinks\nIndicators for monitoring the Millennium Development Goals: definitions, rationale, concepts and sources. New York (NY): United Nations; 2012 (accessed 29 March 2015).\n\t\n\nLinks\nNext generation indicators reference guide: planning and reporting. Version 1.2. Washington (DC): The President’s Emergency Plan for AIDS Relief; 2013 (accessed 29 March 2014).\n\t\n\nLinks\nSpectrum software. Glastonbury (CT): Avenir Health. (accessed 29 March 2015).\n\t\n\nComments\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:42,2018-03-23 12:44:42,2694,"Indicator name
Estimated antiretroviral therapy coverage among people living with HIV (%)
Name abbreviated
ART coverage among people living with HIV (%)
Data Type Representation
Percent
Topic
Health service coverage
ISO Health Indicators Framework
Rationale
Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with HIV infection. As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Over recent years WHO has issued various updates in the ARV guidelines. Under the 2013 WHO consolidated guidelines, roughly 85% people living with HIV would be eligible for treatment in 2013. For reasons of comparibility across countries and over time in the context of changing recommendations, this indicator relates to the number of people receiving ART as of proportion of the overall estimated number of people living with HIV. The ranges around the levels of people living with HIV who received ART are based on the uncertainty bounds around the estimates of people living with HIV.
Definition
Percentage of people living with HIV currently receiving ART among the estimated number of adults and children living with HIV. Numerator: Number of adults and children who are currently receiving ART at the end of the reporting period. Denominator: Estimated number of adults and children living with HIV.
Associated terms
Antiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO standards). ARV regimen prescribed for post exposure prophylaxis are excluded.
Associated terms
Human Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.
Preferred data sources
Facility reporting system
Other possible data sources
Sentinel surveillance sites
Other possible data sources
Population-based surveys
Method of measurement
Numerator: The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Data can be collected from facility-based ART registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving ART in the private sector and public sector should be included in the numerator where data are available.
Denominator: The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) ART. This estimation must take into consideration a variety of factors, including, but not limited to, the current number of people with HIV, the current number of patients on ART and the natural history of HIV from infection to enrolment on ART. A standard modelling HIV estimation method, such as in the Spectrum model, is recommended.
Method of estimation
Modelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of people living with HIV and national programme records are used to determine the number receiving treatment. UNAIDS supports most countries to produce estimates of the number of people living with HIV annually using Spectrum.
M&E Framework
Outcome
Method of estimation of global and regional aggregates
Regional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people living with HIV. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no estimates have been established for most high-income countries. Aggregated coverage percentages are based solely on low- and middle-income countries.
Disaggregation
Age: 1. Minimum for paper-based (routine): less than 15, 15+; 2. Annual data extraction of disaggregated data if not reported routinely: less than 5, 5–9, 10–14, 15–19, 20–24, 25–49, 50+; 3. Electronic system: 5-year age groups
Disaggregation
Sex
Disaggregation
Geographic location
Disaggregation
Key populations (men who have sex with men, sex workers, people who inject drugs, transgender people, prisoners)
Disaggregation
Provider type (public/private)
Disaggregation
Regimen type (e.g. first line, second line)
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Annual
Limitations
Estimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.
To analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of people living with HIV. Specialized software is used to generate uncertainty ranges around estimates. Depending on the quality of surveillance data, the ranges for some countries can be large.
Links
Consolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015).
Links
Framework of actions for the follow-up to the Programme of Action of the International Conference on Population and Development beyond 2014. Report of the Secretary-General. New York (NY): United Nations; 2014 (accessed 19 August 2014).
Links
Global AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016.
Links
Indicators for monitoring the Millennium Development Goals: definitions, rationale, concepts and sources. New York (NY): United Nations; 2012 (accessed 29 March 2015).
Links
Next generation indicators reference guide: planning and reporting. Version 1.2. Washington (DC): The President’s Emergency Plan for AIDS Relief; 2013 (accessed 29 March 2014).
Links
Spectrum software. Glastonbury (CT): Avenir Health. (accessed 29 March 2015).
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13824,15382,Congenital syphilis rate per 100 000 live births,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nCongenital syphilis rate\n\nName abbreviated\n\n \n\nData Type Representation\nRate\n\nTopic\nMorbidity\n\nISO Health Indicators Framework\n\n \n\nRationale\nUntreated syphilis infection in pregnancy can lead to stillbirth, neonatal death, and congenital disease (collectively defined as \""congenital syphilis\"") and also increase risk of HIV transmission and acquisition in the mother and the infant. Given the high efficacy, simplicity, and low cost of syphilis testing and treatment, global and regional initiatives to eliminate mother-to-child transmission (MTCT) of syphilis have been launched. The rate of congenital syphilis is a measure of the impact of programmatic interventions to eliminate MTCT of syphilis.\n\nDefinition\nCongenital syphilis rate expressed per 100,000 live births.\nNumerator: Number of reported congenital syphilis cases (live births and stillbirth) in the past 12 months.\nDenominator: Number of live births\n\nAssociated terms\n\n \n\nPreferred data sources\nSurveillance systems\n\nPreferred data sources\nFacility reporting system\n\nOther possible data sources\n\n \n\nMethod of measurement\nCountries are encouraged to report on this indicator based on a national case definition that is compatible with the global surveillance case definition for congenital syphilis. \n\nMethod of estimation\nData from routine programmatic studies and reporting systems are collected nationally and regionally. WHO compiles this data through its system of monitoring and reporting on global progress in countries' health sector responses toward universal access to HIV prevention, treatment, care and support. WHO, UNICEF, and UNAIDS provide joint support as a component of the Global HIV/AIDS Response Progress Report.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\nWeighted averages using number of live births as the weight.\n\nDisaggregation\n\n \n\nUnit of Measure\nCases per 100 000 live births\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\nAnnual\n\nLimitations\nDiagnosis of congenital syphilis is most reliable when using specific diagnostic tests that are seldom available even in developed countries. Therefore, in most countries diagnosis of congenital syphilis relies on clinical history and examination, making surveillance challenging. Although WHO has a global case definition for surveillance purposes, actual case definition may vary between and within countries and regions. Given the difficulties in diagnosing congenital syphilis, and depending on the case definition used, either underreporting or overreporting can be a problem. The likely magnitude of such reporting errors should always be considered when looking at rates of congenital syphilis. However, with use of a consistent case definition, trends over time may be useful.\n\nLinks\nProgress report 2011: Global HIV/AIDS response (WHO, UNICEF, UNAIDS, 2011)\n\nLinks\nA guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS (WHO, UNICEF, UNAIDS, 2012)\n\nLinks\nMethods for surveillance and monitoring of congenital syphilis elimination within existing systems (WHO, 2011)\n\nLinks\nGlobal guidance on criteria and processes for validation of elimination of mother-to-child transmission of HIV and syphilis\n\nComments\nIt is important that countries when reporting syphilis communicate on the extent to which the data are felt to be representative of the national population. If a country is unable to report on the denominator, WHO will use the denominator as per the UN Ppopulation Division.\n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:41,2018-03-23 12:44:41,2694,"Indicator name
Congenital syphilis rate
Name abbreviated
Data Type Representation
Rate
Topic
Morbidity
ISO Health Indicators Framework
Rationale
Untreated syphilis infection in pregnancy can lead to stillbirth, neonatal death, and congenital disease (collectively defined as ""congenital syphilis"") and also increase risk of HIV transmission and acquisition in the mother and the infant. Given the high efficacy, simplicity, and low cost of syphilis testing and treatment, global and regional initiatives to eliminate mother-to-child transmission (MTCT) of syphilis have been launched. The rate of congenital syphilis is a measure of the impact of programmatic interventions to eliminate MTCT of syphilis.
Definition
Congenital syphilis rate expressed per 100,000 live births.
Numerator: Number of reported congenital syphilis cases (live births and stillbirth) in the past 12 months.
Denominator: Number of live births
Associated terms
Preferred data sources
Surveillance systems
Preferred data sources
Facility reporting system
Other possible data sources
Method of measurement
Countries are encouraged to report on this indicator based on a national case definition that is compatible with the global surveillance case definition for congenital syphilis.
Method of estimation
Data from routine programmatic studies and reporting systems are collected nationally and regionally. WHO compiles this data through its system of monitoring and reporting on global progress in countries' health sector responses toward universal access to HIV prevention, treatment, care and support. WHO, UNICEF, and UNAIDS provide joint support as a component of the Global HIV/AIDS Response Progress Report.
M&E Framework
Method of estimation of global and regional aggregates
Weighted averages using number of live births as the weight.
Disaggregation
Unit of Measure
Cases per 100 000 live births
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Annual
Limitations
Diagnosis of congenital syphilis is most reliable when using specific diagnostic tests that are seldom available even in developed countries. Therefore, in most countries diagnosis of congenital syphilis relies on clinical history and examination, making surveillance challenging. Although WHO has a global case definition for surveillance purposes, actual case definition may vary between and within countries and regions. Given the difficulties in diagnosing congenital syphilis, and depending on the case definition used, either underreporting or overreporting can be a problem. The likely magnitude of such reporting errors should always be considered when looking at rates of congenital syphilis. However, with use of a consistent case definition, trends over time may be useful.
Links
Progress report 2011: Global HIV/AIDS response (WHO, UNICEF, UNAIDS, 2011)
Links
A guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS (WHO, UNICEF, UNAIDS, 2012)
Links
Methods for surveillance and monitoring of congenital syphilis elimination within existing systems (WHO, 2011)
Links
Global guidance on criteria and processes for validation of elimination of mother-to-child transmission of HIV and syphilis
Comments
It is important that countries when reporting syphilis communicate on the extent to which the data are felt to be representative of the national population. If a country is unable to report on the denominator, WHO will use the denominator as per the UN Ppopulation Division.
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13788,15346,Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%),"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nAntiretroviral therapy coverage among people with advanced HIV infection (%)\n\nName abbreviated\nAntiretroviral therapy coverage among people with advanced HIV infection (%)\n\nData Type Representation\nPercent\n\nTopic\nHealth service coverage\n\nISO Health Indicators Framework\n\n \n\nRationale\nAs the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with advanced HIV infection.\n\nDefinition\nThe percentage of adults and children with advanced HIV infection currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocols (or WHO/UNAIDS standards) among the estimated number of adults and children with advanced HIV infection.\n \nNumerator: Number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period\nDenominator: Estimated number of adults and children with advanced HIV infection\n\nAssociated terms\nAntiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO/UNAIDS standards). ARV regimen prescribed for post exposure prophylaxis are excluded.\n\nAssociated terms\nHuman Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.\n\nPreferred data sources\nFacility reporting system\n\nPreferred data sources\nAdministrative reporting system\n\nPreferred data sources\nSurveillance systems\n\nOther possible data sources\n\n \n\nMethod of measurement\nNumerator\nThe numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Antiretroviral therapy taken only for the purpose of prevention of mother-to-child transmission and post-exposure prophylaxis are not included in this indicator. HIV-infected pregnant women who are eligible for antiretroviral therapy and on antiretroviral therapy for their own treatment are included in this indicator.\nThe number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy can be obtained through data collected from facility-based antiretroviral therapy registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving antiretroviral therapy in the private sector and public sector should be included in the numerator where data are available.\n\nDenominator\nThe denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) antiretroviral therapy. This estimation must take into consideration a variety of factors including, but not limited to, the current numbers of people with HIV, the current number of patients on antiretroviral therapy, and the natural history of HIV from infection to enrolment on antiretroviral therapy. A standard modelling method is recommended. The Estimation and Projection Package (EPP)* and Spectrum*, softwares have been developed by the UNAIDS/WHO Reference Group on Estimates, Models and Projections. Need or eligibility for antiretroviral therapy should follow the WHO definitions for the diagnosis of advanced HIV (including AIDS) for adults and children.\n\n(UNAIDS, 2009)\n\nMethod of estimation\nWHO, UNAIDS and UNICEF are responsible for reporting data for this indicator at the international level, and have been compiling country specific data since 2003.\n \nThe data from countries are collected through three international monitoring and reporting processes.\n1. Health sector response to HIV/AIDS (WHO/UNAIDS/UNICEF)\n3. UNGASS Declaration of Commitment on HIV/AIDS (UNAIDS)\nBoth processes are linked through common indicators and a harmonized timeline for reporting. \n \nEstimating the numerator\nData for the calculation of the numerator are compiled from the most recent reports received by WHO and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services. \n \nEstimating the denominator\nThe number of people who need antiretroviral therapy in a country is estimated using statistical modelling methods. \n\nIn response to the emergence of new scientific evidence, in December 2009 WHO updated its antiretroviral therapy guidelines for adults and adolescents. According to the new guidelines, which were developed in consultation with multiple technical and implementing partners, all adolescents and adults, including pregnant women, with HIV infection and a CD4 count at or below 350 cells/mm3 should be started on antiretroviral therapy, regardless of whether or not they have clinical symptoms. Those with severe or advanced clinical disease (WHO clinical stage 3 or 4) should start antiretroviral therapy irrespective of CD4 cell count. \n\nIn order to compare the impact of the new guildelines, both sets of needs for the year 2009 are included, i.e. estimated needs estimated based on a threshold for initiation of antiretroviral therapy with < 200 cells/mm3 (old guidelines) as well as < 350 cells/mm3 (new guidelines).\n \nEstimating antiretroviral therapy coverage\nThe estimates of antiretroviral therapy coverage presented here are calculated by dividing the estimated number of people receiving antiretroviral therapy as of December by the number of people estimated to need treatment in same year (based on UNAIDS/WHO methods). \n\nPredominant type of statistics: predicted\n \n\nM&E Framework\nOutcome\n\nMethod of estimation of global and regional aggregates\nRegional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people needing antiretroviral therapy. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no need numbers have been established for these countries. Aggregated coverage percentages are based solely on low- and middle-income countries.\n\nDisaggregation\nSex\n\nDisaggregation\nAge\n\nDisaggregation\nProvider type (public/private)\n\nUnit of Measure\nN/A\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\n\n \n\nLimitations\nEstimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.\nTo analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of treatment need. Specialized software is used to generate uncertainty ranges around estimates for antiretroviral therapy need. Depending on the quality of surveillance data, the ranges for some countries can be large.\n\nLinks\nHIV/AIDS Data and Statistics (WHO)\n\nLinks\nMethods and assumptions for HIV estimates (UNAIDS)\n\nLinks\n2008 Report on the Global AIDS epidemics (UNAIDS, 2008)\n\nLinks\nGuidelines on Construction of Core Indicators: 2010 Reporting (UNAIDS, 2009)\n\nLinks\nTools for collecting data on the health sector response to HIV/AIDS in 2010 (WHO, 2010)\n\nLinks\n in Current Opinion in HIV and AIDS: Vol.5 Issue 1 p 97–102)\n\nLinks\nTowards universal access - Scaling up priority HIV/AIDS interventions in the health sector (WHO/UNAIDS/UNICEF, 2010)\n\nComments\nThis indicator permits monitoring trends in coverage but does not attempt to distinguish between different forms of antiretroviral therapy or to measure the cost, quality or effectiveness of treatment provided. These will each vary within and between countries and are liable to change over time.\n\nThe degree of utilization of antiretroviral therapy will depend on factors such as cost relative to local incomes, service delivery infrastructure and quality, availability and uptake of voluntary counseling and testing services, and perceptions of effectiveness and possible side effects of treatment.\n(UNAIDS, 2009)\n\nLatest country specific coverage for 2008 were not published as treatment guidelines have been revised, and the effects on treatment need for adults are currently being assessed.\n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:30,2018-03-23 12:44:30,2694,"Indicator name
Antiretroviral therapy coverage among people with advanced HIV infection (%)
Name abbreviated
Antiretroviral therapy coverage among people with advanced HIV infection (%)
Data Type Representation
Percent
Topic
Health service coverage
ISO Health Indicators Framework
Rationale
As the HIV epidemic matures, increasing numbers of people are reaching advanced stages of HIV infection. Antiretroviral therapy (ART) has been shown to reduce mortality among those infected and efforts are being made to make it more affordable within low- and middle-income countries. This indicator assesses the progress in providing antiretroviral combination therapy to all people with advanced HIV infection.
Definition
The percentage of adults and children with advanced HIV infection currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocols (or WHO/UNAIDS standards) among the estimated number of adults and children with advanced HIV infection.
Numerator: Number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) at the end of the reporting period
Denominator: Estimated number of adults and children with advanced HIV infection
Associated terms
Antiretroviral treatment : The use of a combination of 3 or more antiretroviral drugs for purpose of treatment in accordance with nationally approved treatment protocols (or WHO/UNAIDS standards). ARV regimen prescribed for post exposure prophylaxis are excluded.
Associated terms
Human Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.
Preferred data sources
Facility reporting system
Preferred data sources
Administrative reporting system
Preferred data sources
Surveillance systems
Other possible data sources
Method of measurement
Numerator
The numerator can be generated by counting the number of adults and children who received antiretroviral combination therapy at the end of the reporting period. Antiretroviral therapy taken only for the purpose of prevention of mother-to-child transmission and post-exposure prophylaxis are not included in this indicator. HIV-infected pregnant women who are eligible for antiretroviral therapy and on antiretroviral therapy for their own treatment are included in this indicator.
The number of adults and children with advanced HIV infection who are currently receiving antiretroviral combination therapy can be obtained through data collected from facility-based antiretroviral therapy registers or drug supply management systems. These are then tallied and transferred to cross-sectional monthly or quarterly reports which can then be aggregated for national totals. Patients receiving antiretroviral therapy in the private sector and public sector should be included in the numerator where data are available.
Denominator
The denominator is generated by estimating the number of people with advanced HIV infection requiring (in need of/eligible for) antiretroviral therapy. This estimation must take into consideration a variety of factors including, but not limited to, the current numbers of people with HIV, the current number of patients on antiretroviral therapy, and the natural history of HIV from infection to enrolment on antiretroviral therapy. A standard modelling method is recommended. The Estimation and Projection Package (EPP)* and Spectrum*, softwares have been developed by the UNAIDS/WHO Reference Group on Estimates, Models and Projections. Need or eligibility for antiretroviral therapy should follow the WHO definitions for the diagnosis of advanced HIV (including AIDS) for adults and children.
(UNAIDS, 2009)
Method of estimation
WHO, UNAIDS and UNICEF are responsible for reporting data for this indicator at the international level, and have been compiling country specific data since 2003.
The data from countries are collected through three international monitoring and reporting processes.
1. Health sector response to HIV/AIDS (WHO/UNAIDS/UNICEF)
3. UNGASS Declaration of Commitment on HIV/AIDS (UNAIDS)
Both processes are linked through common indicators and a harmonized timeline for reporting.
Estimating the numerator
Data for the calculation of the numerator are compiled from the most recent reports received by WHO and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services.
Estimating the denominator
The number of people who need antiretroviral therapy in a country is estimated using statistical modelling methods.
In response to the emergence of new scientific evidence, in December 2009 WHO updated its antiretroviral therapy guidelines for adults and adolescents. According to the new guidelines, which were developed in consultation with multiple technical and implementing partners, all adolescents and adults, including pregnant women, with HIV infection and a CD4 count at or below 350 cells/mm3 should be started on antiretroviral therapy, regardless of whether or not they have clinical symptoms. Those with severe or advanced clinical disease (WHO clinical stage 3 or 4) should start antiretroviral therapy irrespective of CD4 cell count.
In order to compare the impact of the new guildelines, both sets of needs for the year 2009 are included, i.e. estimated needs estimated based on a threshold for initiation of antiretroviral therapy with < 200 cells/mm3 (old guidelines) as well as < 350 cells/mm3 (new guidelines).
Estimating antiretroviral therapy coverage
The estimates of antiretroviral therapy coverage presented here are calculated by dividing the estimated number of people receiving antiretroviral therapy as of December by the number of people estimated to need treatment in same year (based on UNAIDS/WHO methods).
Predominant type of statistics: predicted
M&E Framework
Outcome
Method of estimation of global and regional aggregates
Regional and global estimates are calculated as weighted averages of the country level indicator where the weights correspond to each country’s share of the total number of people needing antiretroviral therapy. Although WHO and UNAIDS collect data on the number of people receiving antiretroviral therapy in high-income countries, as of 2007, no need numbers have been established for these countries. Aggregated coverage percentages are based solely on low- and middle-income countries.
Disaggregation
Sex
Disaggregation
Age
Disaggregation
Provider type (public/private)
Unit of Measure
N/A
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Limitations
Estimating the number of people receiving antiretroviral therapy involves some uncertainty in countries that have not yet established regular reporting systems that can capture data on people who initiate treatment for the first time, rates of adherence among people who receive treatment, people who discontinue treatment, and those who die.
To analyse and compare antiretroviral therapy coverage across countries, international agencies use standardized estimates of treatment need. Specialized software is used to generate uncertainty ranges around estimates for antiretroviral therapy need. Depending on the quality of surveillance data, the ranges for some countries can be large.
Links
HIV/AIDS Data and Statistics (WHO)
Links
Methods and assumptions for HIV estimates (UNAIDS)
Links
2008 Report on the Global AIDS epidemics (UNAIDS, 2008)
Links
Guidelines on Construction of Core Indicators: 2010 Reporting (UNAIDS, 2009)
Links
Tools for collecting data on the health sector response to HIV/AIDS in 2010 (WHO, 2010)
Links
in Current Opinion in HIV and AIDS: Vol.5 Issue 1 p 97–102)
Links
Towards universal access - Scaling up priority HIV/AIDS interventions in the health sector (WHO/UNAIDS/UNICEF, 2010)
Comments
This indicator permits monitoring trends in coverage but does not attempt to distinguish between different forms of antiretroviral therapy or to measure the cost, quality or effectiveness of treatment provided. These will each vary within and between countries and are liable to change over time.
The degree of utilization of antiretroviral therapy will depend on factors such as cost relative to local incomes, service delivery infrastructure and quality, availability and uptake of voluntary counseling and testing services, and perceptions of effectiveness and possible side effects of treatment.
(UNAIDS, 2009)
Latest country specific coverage for 2008 were not published as treatment guidelines have been revised, and the effects on treatment need for adults are currently being assessed.
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13775,15333,"People aged 15 years and over who received HIV testing and counselling, estimated number per 1000 adult population","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nPeople aged 15 years and over who received HIV testing and counselling (estimated per 1000 population)\n\nName abbreviated\n\n \n\nData Type Representation\nRate\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\nIn order to protect themselves and to prevent infecting others, it is important for individuals to know their\nHIV status. Knowledge of one’s status is also a critical factor in the decision to seek treatment.\n\nDefinition\nEstimated number of people aged 15 years and over who received HIV testing and counselling during the last 12 months per 1000 adults.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nNumerator: Program service statistics compiled from routine reports of the number of people tested and know the results from all service points, including voluntary counselling and testing (VCT) sites, clinics, hospitals, and NGO outreach points, etc., (excluding mandatory T&C) which are often aggregated at the district levels and subsequently at the national level. Denominator: Source: UN population division.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nSex\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:20,2018-03-23 12:44:20,2694,"Indicator name
People aged 15 years and over who received HIV testing and counselling (estimated per 1000 population)
Name abbreviated
Data Type Representation
Rate
Topic
ISO Health Indicators Framework
Rationale
In order to protect themselves and to prevent infecting others, it is important for individuals to know their
HIV status. Knowledge of one’s status is also a critical factor in the decision to seek treatment.
Definition
Estimated number of people aged 15 years and over who received HIV testing and counselling during the last 12 months per 1000 adults.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Numerator: Program service statistics compiled from routine reports of the number of people tested and know the results from all service points, including voluntary counselling and testing (VCT) sites, clinics, hospitals, and NGO outreach points, etc., (excluding mandatory T&C) which are often aggregated at the district levels and subsequently at the national level. Denominator: Source: UN population division.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Sex
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13765,15323,Estimated number of children needing antiretroviral therapy based on WHO methods,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated number of children needing antiretroviral therapy based on WHO methods\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\n\n \n\nDefinition\nEstimated number of children eligible for antiretroviral therapy based on WHO methods.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nThe Spectrum software package (WHO/UNAIDS) is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:11,2018-03-23 12:44:11,2694,"Indicator name
Estimated number of children needing antiretroviral therapy based on WHO methods
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Rationale
Definition
Estimated number of children eligible for antiretroviral therapy based on WHO methods.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
The Spectrum software package (WHO/UNAIDS) is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13763,15321,Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\nThe risk for mother-to-child transmission can be reduced significantly by the complementary approaches\nof providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral\nprophylaxis to the infant and using safe delivery practices and safer infant feeding.\n\nDefinition\nEstimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nThe number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-child transmission\nis estimated using standardized statistical modelling based on UNAIDS/WHO methods that consider various epidemic and\ndemographic parameters and the national programme coverage of antiretroviral therapy in the country, such as the HIV prevalence\namong women of reproductive age and the effect of HIV on fertility and antiretroviral therapy coverage. These statistical modelling\nprocedures are used to derive a comprehensive population-based estimate of the total number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-child transmission in the country.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:11,2018-03-23 12:44:11,2694,"Indicator name
Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Rationale
The risk for mother-to-child transmission can be reduced significantly by the complementary approaches
of providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral
prophylaxis to the infant and using safe delivery practices and safer infant feeding.
Definition
Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
The number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-child transmission
is estimated using standardized statistical modelling based on UNAIDS/WHO methods that consider various epidemic and
demographic parameters and the national programme coverage of antiretroviral therapy in the country, such as the HIV prevalence
among women of reproductive age and the effect of HIV on fertility and antiretroviral therapy coverage. These statistical modelling
procedures are used to derive a comprehensive population-based estimate of the total number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-child transmission in the country.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13748,15306,Reported number of people receiving antiretroviral therapy,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nReported number of people receiving antiretroviral therapy\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nAccessibility\n\nRationale\n\n \n\nDefinition\nNumber of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nProgramme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nSex\n\nDisaggregation\nAge : <15\n\nDisaggregation\nAge : 15+\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:09,2018-03-23 12:44:09,2694,"Indicator name
Reported number of people receiving antiretroviral therapy
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Accessibility
Rationale
Definition
Number of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Programme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Sex
Disaggregation
Age : <15
Disaggregation
Age : 15+
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13747,15305,Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated pregnant women living with HIV who received antiretroviral medicine for preventing mother-to-child transmission (%)\n\t\n\nName abbreviated\nPrevention of mother-to-child transmission\n\nData Type Representation\nPercent\n\nTopic\n \n\nISO Health Indicators Framework\n\n \n\nRationale\nThe risk for mother-to-child transmission can be reduced significantly by the complementary approaches of providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral prophylaxis to the infant and using safe delivery practices and safer infant feeding.The data will be used to track progress toward global and national goals towards elimination of mother-to-child transmission; to inform policy and strategic planning; for advocacy; and leveraging resources for accelerated scale up.\n\t\n\nDefinition\nPercentage of HIV-positive pregnant women provided with ART to reduce the risk of mother-to-child transmission during pregnancy. Numerator: Number of HIV-positive pregnant women who received ARV as recommended by WHO. Denominator: Estimated number of HIV-positive pregnant women\n\t\n\nAssociated terms\n \n\nPreferred data sources\nRoutine facility information systems and modelled estimates of the number of HIV-positive pregnant women.\n\nOther possible data sources\nAIDSinfo. (http://aidsinfo.unaids.org/, accessed 5 April 2016).\n \n\nMethod of measurement\nThe numerator can be calculated from national programme records aggregated from programme monitoring tools, such as patient registers and summary reporting forms. The denominator of the estimated number of HIV-positive pregnant women is typically obtained using Spectrum, a UNAIDS-supported software tool. Countries with routine antenatal clinic surveillance, in combination with appropriate adjustments related to demographic data and coverage of antenatal care, may be able to use these data to estimate the denominator\n \t\n\nMethod of estimation\nModelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of HIV-positive pregnant women and national programme records are used to determine the number receiving ARV. UNAIDS supports most countries to produce estimates of the number of HIV-positive pregnant women annually using Spectrum\n\nM&E Framework\nOutcome\n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nTreatment status at time of pregnancy (already receiving or initiated during pregnancy) \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\nAnnual (unless survey-based) \n\nLimitations\n \n\nLinks\nGlobal AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016.\n\nLinks\nConsolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015).\n\nLinks\nGlobal AIDS response progress reporting 2016: Construction of core indicators for monitoring the 2011 United Nations Political Declaration on HIV and AIDS. Geneva: Joint United Nations Programme on HIV/AIDS, 2016 (accessed 2 April 2016)\n\nLinks\nSpectrum manual. Glastonbury (CT): Avenir Health. (accessed 2 April 2016).\n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:09,2018-03-23 12:44:09,2694,"Indicator name
Estimated pregnant women living with HIV who received antiretroviral medicine for preventing mother-to-child transmission (%)
Name abbreviated
Prevention of mother-to-child transmission
Data Type Representation
Percent
Topic
ISO Health Indicators Framework
Rationale
The risk for mother-to-child transmission can be reduced significantly by the complementary approaches of providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral prophylaxis to the infant and using safe delivery practices and safer infant feeding.The data will be used to track progress toward global and national goals towards elimination of mother-to-child transmission; to inform policy and strategic planning; for advocacy; and leveraging resources for accelerated scale up.
Definition
Percentage of HIV-positive pregnant women provided with ART to reduce the risk of mother-to-child transmission during pregnancy. Numerator: Number of HIV-positive pregnant women who received ARV as recommended by WHO. Denominator: Estimated number of HIV-positive pregnant women
Associated terms
Preferred data sources
Routine facility information systems and modelled estimates of the number of HIV-positive pregnant women.
Other possible data sources
AIDSinfo. (http://aidsinfo.unaids.org/, accessed 5 April 2016).
Method of measurement
The numerator can be calculated from national programme records aggregated from programme monitoring tools, such as patient registers and summary reporting forms. The denominator of the estimated number of HIV-positive pregnant women is typically obtained using Spectrum, a UNAIDS-supported software tool. Countries with routine antenatal clinic surveillance, in combination with appropriate adjustments related to demographic data and coverage of antenatal care, may be able to use these data to estimate the denominator
Method of estimation
Modelling, using multiple inputs specific to the HIV epidemic context, is typically used to obtain an estimate of the number of HIV-positive pregnant women and national programme records are used to determine the number receiving ARV. UNAIDS supports most countries to produce estimates of the number of HIV-positive pregnant women annually using Spectrum
M&E Framework
Outcome
Method of estimation of global and regional aggregates
Disaggregation
Treatment status at time of pregnancy (already receiving or initiated during pregnancy)
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Annual (unless survey-based)
Limitations
Links
Global AIDS Monitoring 2017 Indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS(UNAIDS/WHO/UNICEF), 2016.
Links
Consolidated Strategic Information Guidelines for HIV in the Health Sector. Geneva: World Health Organization; 2015 (accessed 10 June 2015).
Links
Global AIDS response progress reporting 2016: Construction of core indicators for monitoring the 2011 United Nations Political Declaration on HIV and AIDS. Geneva: Joint United Nations Programme on HIV/AIDS, 2016 (accessed 2 April 2016)
Links
Spectrum manual. Glastonbury (CT): Avenir Health. (accessed 2 April 2016).
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13736,15294,Congenital syphilis number of reported cases,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nCongenital syphilis - number of reported cases \n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\nMorbidity\n\nISO Health Indicators Framework\n\n \n\nRationale\nUntreated syphilis infection in pregnancy can lead to stillbirth, neonatal death, and congenital disease (collectively defined as \""congenital syphilis\"") and also increase risk of HIV transmission and acquisition in the mother and the infant. Given the high efficacy, simplicity, and low cost of syphilis testing and treatment, global and regional initiatives to eliminate mother-to-child transmission (MTCT) of syphilis have been launched. The rate of congenital syphilis is a measure of the impact of programmatic interventions to eliminate MTCT of syphilis.\n\nDefinition\nNumber of reported congenital syphilis cases (live births and stillbirth) in the past 12 months. \n\nAssociated terms\n\n \n\nPreferred data sources\nSurveillance systems\n\nPreferred data sources\nFacility reporting system\n\nOther possible data sources\n\n \n\nMethod of measurement\nCountries are encouraged to report on this indicator based on a national case definition that is compatible with the global surveillance case definition for congenital syphilis. \n\nMethod of estimation\nData from routine programmatic studies and reporting systems are collected nationally and regionally. WHO compiles this data through its system of monitoring and reporting on global progress in countries' health sector responses toward universal access to HIV prevention, treatment, care and support. WHO, UNICEF, and UNAIDS provide joint support as a component of the Global HIV/AIDS Response Progress Report.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\nSum of country values.\n\nDisaggregation\n\n \n\nUnit of Measure\nCases\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\nAnnual\n\nLimitations\nDiagnosis of congenital syphilis is most reliable when using specific diagnostic tests that are seldom available even in developed countries. Therefore, in most countries diagnosis of congenital syphilis relies on clinical history and examination, making surveillance challenging. Although WHO has a global case definition for surveillance purposes, actual case definition may vary between and within countries and regions. Given the difficulties in diagnosing congenital syphilis, and depending on the case definition used, either underreporting or overreporting can be a problem. The likely magnitude of such reporting errors should always be considered when looking at rates of congenital syphilis. However, with use of a consistent case definition, trends over time may be useful.\n\nLinks\nProgress report 2011: Global HIV/AIDS response (WHO, UNICEF, UNAIDS, 2011)\n\nLinks\nA guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS (WHO, UNICEF, UNAIDS, 2012)\n\nLinks\nMethods for surveillance and monitoring of congenital syphilis elimination within existing systems (WHO, 2011)\n\nLinks\nGlobal guidance on criteria and processes for validation of elimination of mother-to-child transmission of HIV and syphilis\n\nComments\nIt is important that countries when reporting syphilis communicate on the extent to which the data are felt to be representative of the national population. \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:08,2018-03-23 12:44:08,2694,"Indicator name
Congenital syphilis - number of reported cases
Name abbreviated
Data Type Representation
Count
Topic
Morbidity
ISO Health Indicators Framework
Rationale
Untreated syphilis infection in pregnancy can lead to stillbirth, neonatal death, and congenital disease (collectively defined as ""congenital syphilis"") and also increase risk of HIV transmission and acquisition in the mother and the infant. Given the high efficacy, simplicity, and low cost of syphilis testing and treatment, global and regional initiatives to eliminate mother-to-child transmission (MTCT) of syphilis have been launched. The rate of congenital syphilis is a measure of the impact of programmatic interventions to eliminate MTCT of syphilis.
Definition
Number of reported congenital syphilis cases (live births and stillbirth) in the past 12 months.
Associated terms
Preferred data sources
Surveillance systems
Preferred data sources
Facility reporting system
Other possible data sources
Method of measurement
Countries are encouraged to report on this indicator based on a national case definition that is compatible with the global surveillance case definition for congenital syphilis.
Method of estimation
Data from routine programmatic studies and reporting systems are collected nationally and regionally. WHO compiles this data through its system of monitoring and reporting on global progress in countries' health sector responses toward universal access to HIV prevention, treatment, care and support. WHO, UNICEF, and UNAIDS provide joint support as a component of the Global HIV/AIDS Response Progress Report.
M&E Framework
Method of estimation of global and regional aggregates
Sum of country values.
Disaggregation
Unit of Measure
Cases
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Annual
Limitations
Diagnosis of congenital syphilis is most reliable when using specific diagnostic tests that are seldom available even in developed countries. Therefore, in most countries diagnosis of congenital syphilis relies on clinical history and examination, making surveillance challenging. Although WHO has a global case definition for surveillance purposes, actual case definition may vary between and within countries and regions. Given the difficulties in diagnosing congenital syphilis, and depending on the case definition used, either underreporting or overreporting can be a problem. The likely magnitude of such reporting errors should always be considered when looking at rates of congenital syphilis. However, with use of a consistent case definition, trends over time may be useful.
Links
Progress report 2011: Global HIV/AIDS response (WHO, UNICEF, UNAIDS, 2011)
Links
A guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS (WHO, UNICEF, UNAIDS, 2012)
Links
Methods for surveillance and monitoring of congenital syphilis elimination within existing systems (WHO, 2011)
Links
Global guidance on criteria and processes for validation of elimination of mother-to-child transmission of HIV and syphilis
Comments
It is important that countries when reporting syphilis communicate on the extent to which the data are felt to be representative of the national population.
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13730,15288,"Testing and counselling facilities, estimated number per 100 000 adult population","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nTesting and counselling facilities, estimated number per 100 000 adult population\n\nName abbreviated\n\n \n\nData Type Representation\nRate\n\nTopic\n\n \n\nISO Health Indicators Framework\nHealth system\n\nRationale\nKnowledge of HIV status is critical to expand access to HIV treatment, care and support, and prevention. Availability of testing and counselling (TC) services is the pre-requisite for scaling up TC coverage so that more people know their HIV status, which can be expanded through voluntary counselling and testing (VCT) and provider initiated testing and counselling (PITC) models.\n\nDefinition\nThe number of health facilities that provide HIV testing and counselling services divided by the estimated adult population per 100 000.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nNumerator: Two possible sources of information: 1) Central register of all Testing and Counselling sites;\n2) Central test procurement records for the number of facilities requesting kits.\n \nDenominator: Source: UN population division.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:07,2018-03-23 12:44:07,2694,"Indicator name
Testing and counselling facilities, estimated number per 100 000 adult population
Name abbreviated
Data Type Representation
Rate
Topic
ISO Health Indicators Framework
Health system
Rationale
Knowledge of HIV status is critical to expand access to HIV treatment, care and support, and prevention. Availability of testing and counselling (TC) services is the pre-requisite for scaling up TC coverage so that more people know their HIV status, which can be expanded through voluntary counselling and testing (VCT) and provider initiated testing and counselling (PITC) models.
Definition
The number of health facilities that provide HIV testing and counselling services divided by the estimated adult population per 100 000.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Numerator: Two possible sources of information: 1) Central register of all Testing and Counselling sites;
2) Central test procurement records for the number of facilities requesting kits.
Denominator: Source: UN population division.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13717,15275,Number of deaths due to HIV/AIDS,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nNumber of deaths due to AIDS\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\n\n \n\nDefinition\nThe estimated number of adults and children that have died due to HIV/AIDS in a specific year.\n\nAssociated terms\n\n \n\nPreferred data sources\nCivil registration with complete coverage and medical certification of cause of death\n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nEmpirical data from different HIV surveillance sources are consolidated to obtain estimates of the level and trend on HIV infection and of mortality in adults and children. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgement needs to be used as to the quality of the data and how representative it is of the population. UNAIDS and WHO produce country-specific estimates of mortality due to HIV/AIDS every two years.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nAge\n\nDisaggregation\nSex\n\nUnit of Measure\nDeaths\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nBiennial (Two years)\n\nExpected frequency of data collection\n\n \n\nLimitations\nAlthough many countries have collected information on mortality in adults and children in recent years, underreporting is a feature of systems in many countries, partly owing to stigma and lack of diagnosis. It is crucial that civil registration systems (completeness of registration) and survey data-collection are of high quality. WHO does estimate the level of underestimation of civil registration systems and there clearly is substantial variation in data quality and consistency between countries.\n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:04,2018-03-23 12:44:04,2694,"Indicator name
Number of deaths due to AIDS
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Rationale
Definition
The estimated number of adults and children that have died due to HIV/AIDS in a specific year.
Associated terms
Preferred data sources
Civil registration with complete coverage and medical certification of cause of death
Other possible data sources
Method of measurement
Method of estimation
Empirical data from different HIV surveillance sources are consolidated to obtain estimates of the level and trend on HIV infection and of mortality in adults and children. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgement needs to be used as to the quality of the data and how representative it is of the population. UNAIDS and WHO produce country-specific estimates of mortality due to HIV/AIDS every two years.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Age
Disaggregation
Sex
Unit of Measure
Deaths
Unit Multiplier
Expected frequency of data dissemination
Biennial (Two years)
Expected frequency of data collection
Limitations
Although many countries have collected information on mortality in adults and children in recent years, underreporting is a feature of systems in many countries, partly owing to stigma and lack of diagnosis. It is crucial that civil registration systems (completeness of registration) and survey data-collection are of high quality. WHO does estimate the level of underestimation of civil registration systems and there clearly is substantial variation in data quality and consistency between countries.
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13694,15252,"Testing and counselling facilities, reported number","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nTesting and counselling facilities, reported number\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nHealth system\n\nRationale\nKnowledge of HIV status is critical to expand access to HIV treatment, care and support, and prevention. Availability of testing and counselling (TC) services is the pre-requisite for scaling up TC coverage so that more people know their HIV status, which can be expanded through voluntary counselling and testing (VCT) and provider initiated testing and counselling (PITC) models.\n\nDefinition\nNumber of health facilities that provide HIV testing and counselling services.\n\nAssociated terms\n\n \n\nPreferred data sources\nFacility registers and other program monitoring tools\n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nTwo possible sources of information:\n 1) Central register of all Testing and Counselling sites;\n2) Central test procurement records for the number of facilities requesting kits.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:44:02,2018-03-23 12:44:02,2694,"Indicator name
Testing and counselling facilities, reported number
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Health system
Rationale
Knowledge of HIV status is critical to expand access to HIV treatment, care and support, and prevention. Availability of testing and counselling (TC) services is the pre-requisite for scaling up TC coverage so that more people know their HIV status, which can be expanded through voluntary counselling and testing (VCT) and provider initiated testing and counselling (PITC) models.
Definition
Number of health facilities that provide HIV testing and counselling services.
Associated terms
Preferred data sources
Facility registers and other program monitoring tools
Other possible data sources
Method of measurement
Method of estimation
Two possible sources of information:
1) Central register of all Testing and Counselling sites;
2) Central test procurement records for the number of facilities requesting kits.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13645,15203,Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nNumber of pregnant women living with HIV who received antiretrovirals (excluding single dose Nevirapine) for preventing mother-to-child transmission\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nAccessibility\n\nRationale\nThe risk for mother-to-child transmission can be reduced significantly by the complementary approaches of providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral prophylaxis to the infant and using safe delivery practices and safer infant feeding.\nThe data will be used to track progress toward global and national goals towards elimination of mothert-to-child transmission; to inform policy and strategic planning; for advocacy; and leveraging resources for accelerated scale up.\n\nDefinition\nNumber of HIV-positive pregnant women who received antiretroviral drugs\nduring the past 12 months to reduce mother-to-child transmission.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nProgramme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:43:50,2018-03-23 12:43:50,2694,"Indicator name
Number of pregnant women living with HIV who received antiretrovirals (excluding single dose Nevirapine) for preventing mother-to-child transmission
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Accessibility
Rationale
The risk for mother-to-child transmission can be reduced significantly by the complementary approaches of providing antiretroviral drugs (as treatment or as prophylaxis) to the mother and antiretroviral prophylaxis to the infant and using safe delivery practices and safer infant feeding.
The data will be used to track progress toward global and national goals towards elimination of mothert-to-child transmission; to inform policy and strategic planning; for advocacy; and leveraging resources for accelerated scale up.
Definition
Number of HIV-positive pregnant women who received antiretroviral drugs
during the past 12 months to reduce mother-to-child transmission.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Programme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13591,15149,Reported number of children receiving antiretroviral therapy,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nReported number of people receiving antiretroviral therapy\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nAccessibility\n\nRationale\n\n \n\nDefinition\nNumber of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nProgramme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nSex\n\nDisaggregation\nAge : <15\n\nDisaggregation\nAge : 15+\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:43:45,2018-03-23 12:43:45,2694,"Indicator name
Reported number of people receiving antiretroviral therapy
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Accessibility
Rationale
Definition
Number of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Programme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Sex
Disaggregation
Age : <15
Disaggregation
Age : 15+
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13590,15148,"Reported number of children receiving antiretroviral therapy, month and year of report","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nReported number of people receiving antiretroviral therapy\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nAccessibility\n\nRationale\n\n \n\nDefinition\nNumber of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nProgramme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nSex\n\nDisaggregation\nAge : <15\n\nDisaggregation\nAge : 15+\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:43:45,2018-03-23 12:43:45,2694,"Indicator name
Reported number of people receiving antiretroviral therapy
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Accessibility
Rationale
Definition
Number of eligible adults and children currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO standards) at the end of the reporting period.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Programme monitoring: facility-based antiretroviral therapy registers or drug supply management systems.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Sex
Disaggregation
Age : <15
Disaggregation
Age : 15+
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13567,15125,Prevalence of HIV among adults aged 15 to 49 (%),"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nHIV prevalence among adults aged 15-49 years (%)\n\nName abbreviated\n\n \n\nData Type Representation\nPercent\n\nTopic\nMorbidity\n\nISO Health Indicators Framework\n\n \n\nRationale\nHIV and AIDS has become a major public health problem in many countries and monitoring the course of the epidemic and impact of interventions is crucial. Both the Millennium Development Goals (MDG) and the United Nations General Assembly Special Session on HIV and AIDS (UNGASS) have set goals of reducing HIV prevalence.\n\nDefinition\nThe estimated number of adults aged 15-49 years with HIV infection, whether or not they have developed symptoms of AIDS, expressed as per cent of total population in that age group.\n\nAssociated terms\nHuman Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.\n\nPreferred data sources\nHousehold surveys\n\nPreferred data sources\nSurveillance systems\n\nOther possible data sources\n\n \n\nMethod of measurement\nStandardized tools and methods of estimation have been developed by UNAIDS and WHO in collaboration with the UNAIDS Reference Group on Estimation, Modelling and Projections.\n \nIn countries with a generalized epidemic, national estimates of HIV prevalence are based on data generated by surveillance systems that focus on pregnant women who attend a selected number of sentinel antenatal clinics, and in an increasing number of countries on nationally representative serosurveys. In countries with a low level or concentrated epidemic national estimates of HIV prevalence are primarily based on surveillance data collected from populations at high risk (sex workers, men who have sex with men, injecting drug users) and estimates of the size of populations at high and low risk. This data is entered into the Estimation and Projection Package (EPP) software which fits a simple epidemiological model to the epidemic structure defined. EPP finds the best fitting curve that describes the evolution of adult HIV prevalence over time, and calibrates that curve based on prevalence found in any national surveys or default values in case there is no national survey available. \nFor countries with very little available prevalence data (less than three consistent surveillance sites) a point prevalence estimate and projection is made using spreadsheet models (the Workbook Method). The resulting point prevalence estimates for several years are entered into EPP to find the best fitting curve that describes the evolution of adult HIV prevalence over time.\n \n(http://www.unaids.org/en/KnowledgeCentre/HIVData/Methodology/ , accessed on 2 may 2010)\n\nMethod of estimation\nThe country-specific estimates of adults living with HIV, used as the numerator for this indicator, have been produced by National AIDS Programs and compiled by UNAIDS and WHO. They have been discussed with national AIDS programs for review and comments, but are not necessarily the official estimates used by national governments. For countries where no recent data were available, country-specific estimates have not been listed in the tables. (2008 Report on the Global AIDS epidemics, Annex 1).\n\nPredominant type of statistics: predicted\n\nM&E Framework\nImpact\n\nMethod of estimation of global and regional aggregates\nRegional estimates are weighted averages of the country data, using the number of population aged ≥ 15 years for the reference year in each country as the weight. No figures are reported if less than 50 per cent of the population aged ≥ 15 years in the region are covered.\n\nDisaggregation\nSex\n\nDisaggregation\nLocation (urban/rural)\n\nDisaggregation\nBoundaries : Administrative regions\n\nDisaggregation\nBoundaries : Health regions\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nBiennial (Two years)\n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\nHIV/AIDS Data and Statistics (WHO)\n\nLinks\nGlobal HIV/AIDS Online Database (UNAIDS-WHO)\n\nLinks\nMethods and assumptions for HIV estimates (UNAIDS)\n\nLinks\nImproved data, methods and tools for the 2007 HIV and AIDS estimates and projections (Sex Transm Infect, August 2008, Volume 84, Issue Suppl 1 )\n\nLinks\nUNAIDS Report on the global AIDS epidemic\n\nComments\nThe estimates in the 2008 Report on the Global AIDS epidemics are presented together with ranges, which reflect the certainty associated with each of the estimates. The extent of uncertainty depends mainly on the type of epidemic, and the quality, coverage and consistency of a country’s surveillance system and, in generalized epidemics, whether or not a population-based survey with HIV testing was conducted. \n\nThe main indicator proposed for monitoring progress towards achieving the international goals is HIV prevalence among young people aged 15-24 years, which is a better proxy for monitoring HIV incidence. Although countries are moving towards collecting better data on young people, mainly by capturing data on young pregnant women attending antenatal clinics or national population based surveys, comparable data availability is still limited. Analysis of trends on consistent sites have been proposed as a an alternative to tool to assess recent rends and countries have been encouraged to collect report HIV surveillance data by age breakdown.\n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:43:43,2018-03-23 12:43:43,2694,"Indicator name
HIV prevalence among adults aged 15-49 years (%)
Name abbreviated
Data Type Representation
Percent
Topic
Morbidity
ISO Health Indicators Framework
Rationale
HIV and AIDS has become a major public health problem in many countries and monitoring the course of the epidemic and impact of interventions is crucial. Both the Millennium Development Goals (MDG) and the United Nations General Assembly Special Session on HIV and AIDS (UNGASS) have set goals of reducing HIV prevalence.
Definition
The estimated number of adults aged 15-49 years with HIV infection, whether or not they have developed symptoms of AIDS, expressed as per cent of total population in that age group.
Associated terms
Human Immunodeficiency Virus (HIV) : A virus that weakens the immune system, ultimately leading to AIDS, the acquired immunodeficiency syndrome. HIV destroys the body’s ability to fight off infection and disease, which can ultimately lead to death.
Preferred data sources
Household surveys
Preferred data sources
Surveillance systems
Other possible data sources
Method of measurement
Standardized tools and methods of estimation have been developed by UNAIDS and WHO in collaboration with the UNAIDS Reference Group on Estimation, Modelling and Projections.
In countries with a generalized epidemic, national estimates of HIV prevalence are based on data generated by surveillance systems that focus on pregnant women who attend a selected number of sentinel antenatal clinics, and in an increasing number of countries on nationally representative serosurveys. In countries with a low level or concentrated epidemic national estimates of HIV prevalence are primarily based on surveillance data collected from populations at high risk (sex workers, men who have sex with men, injecting drug users) and estimates of the size of populations at high and low risk. This data is entered into the Estimation and Projection Package (EPP) software which fits a simple epidemiological model to the epidemic structure defined. EPP finds the best fitting curve that describes the evolution of adult HIV prevalence over time, and calibrates that curve based on prevalence found in any national surveys or default values in case there is no national survey available.
For countries with very little available prevalence data (less than three consistent surveillance sites) a point prevalence estimate and projection is made using spreadsheet models (the Workbook Method). The resulting point prevalence estimates for several years are entered into EPP to find the best fitting curve that describes the evolution of adult HIV prevalence over time.
(http://www.unaids.org/en/KnowledgeCentre/HIVData/Methodology/ , accessed on 2 may 2010)
Method of estimation
The country-specific estimates of adults living with HIV, used as the numerator for this indicator, have been produced by National AIDS Programs and compiled by UNAIDS and WHO. They have been discussed with national AIDS programs for review and comments, but are not necessarily the official estimates used by national governments. For countries where no recent data were available, country-specific estimates have not been listed in the tables. (2008 Report on the Global AIDS epidemics, Annex 1).
Predominant type of statistics: predicted
M&E Framework
Impact
Method of estimation of global and regional aggregates
Regional estimates are weighted averages of the country data, using the number of population aged ≥ 15 years for the reference year in each country as the weight. No figures are reported if less than 50 per cent of the population aged ≥ 15 years in the region are covered.
Disaggregation
Sex
Disaggregation
Location (urban/rural)
Disaggregation
Boundaries : Administrative regions
Disaggregation
Boundaries : Health regions
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Biennial (Two years)
Expected frequency of data collection
Limitations
Links
HIV/AIDS Data and Statistics (WHO)
Links
Global HIV/AIDS Online Database (UNAIDS-WHO)
Links
Methods and assumptions for HIV estimates (UNAIDS)
Links
Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections (Sex Transm Infect, August 2008, Volume 84, Issue Suppl 1 )
Links
UNAIDS Report on the global AIDS epidemic
Comments
The estimates in the 2008 Report on the Global AIDS epidemics are presented together with ranges, which reflect the certainty associated with each of the estimates. The extent of uncertainty depends mainly on the type of epidemic, and the quality, coverage and consistency of a country’s surveillance system and, in generalized epidemics, whether or not a population-based survey with HIV testing was conducted.
The main indicator proposed for monitoring progress towards achieving the international goals is HIV prevalence among young people aged 15-24 years, which is a better proxy for monitoring HIV incidence. Although countries are moving towards collecting better data on young people, mainly by capturing data on young pregnant women attending antenatal clinics or national population based surveys, comparable data availability is still limited. Analysis of trends on consistent sites have been proposed as a an alternative to tool to assess recent rends and countries have been encouraged to collect report HIV surveillance data by age breakdown.
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13448,15006,"Number of people aged 15 years and over who received HIV testing and counselling, reported number","{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nReported number of people aged 15 years and over who received HIV testing and counselling\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\nIn order to protect themselves and to prevent infecting others, it is important for individuals to know their\nHIV status. Knowledge of one’s status is also a critical factor in the decision to seek treatment.\n\nDefinition\nNumber of people aged 15 years and over who received HIV testing and counselling during the last 12 months.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nProgram service statistics compiled from routine reports of the number of people tested and know the results from all service points, including voluntary counselling and testing (VCT) sites, clinics, hospitals, and NGO outreach points, etc., (excluding mandatory T&C) which are often aggregated at the district levels and subsequently at the national level.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nSex\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:42:58,2018-03-23 12:42:58,2694,"Indicator name
Reported number of people aged 15 years and over who received HIV testing and counselling
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Rationale
In order to protect themselves and to prevent infecting others, it is important for individuals to know their
HIV status. Knowledge of one’s status is also a critical factor in the decision to seek treatment.
Definition
Number of people aged 15 years and over who received HIV testing and counselling during the last 12 months.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Program service statistics compiled from routine reports of the number of people tested and know the results from all service points, including voluntary counselling and testing (VCT) sites, clinics, hospitals, and NGO outreach points, etc., (excluding mandatory T&C) which are often aggregated at the district levels and subsequently at the national level.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Sex
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13437,14995,Number of new HIV infections,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nNumber of new HIV infections\n\nName abbreviated\nHIV incidence\n\nData Type Representation\nCount\n\nTopic\nMorbidity\n\nISO Health Indicators Framework\n\n \n\nRationale\n\n The number of new infections is important for monitoring both epidemic trends and dynamics within the population. \n \n\nDefinition\n\nThe estimated annual number new HIV infections estimated by the end of a specific year.\n \n\nAssociated terms\n\n \n\nPreferred data sources\nSurveillance systems\n\nOther possible data sources\nHousehold surveys\n\nOther possible data sources\nSpecific population survey\n\nMethod of measurement\n\n\n\tAnalysis of country data on HIV prevalence, particularly among young age groups and, where available, direct HIV incidence data; internationally consistent modelled estimates, e.g. Spectrum AIM.\n \n\nMethod of estimation\n\n\n\tModelled estimates of the number of new HIV infections are produced and compiled by country teams and published annually by UNAIDS and WHO. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgment needs to be used as to the quality of the data and how representative it is of the population.\n \n\nM&E Framework\nImpact\n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nAge\n\nDisaggregation\nSex\n\nUnit of Measure\nCases\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\nAnnual\n\nExpected frequency of data collection\nAnnual\n\nLimitations\n\n \n\nLinks\nConsolidated strategic information guidelines for HIV in the health sector (WHO, 2015)\n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:42:57,2018-03-23 12:42:57,2694,"Indicator name
Number of new HIV infections
Name abbreviated
HIV incidence
Data Type Representation
Count
Topic
Morbidity
ISO Health Indicators Framework
Rationale
The number of new infections is important for monitoring both epidemic trends and dynamics within the population.
Definition
The estimated annual number new HIV infections estimated by the end of a specific year.
Associated terms
Preferred data sources
Surveillance systems
Other possible data sources
Household surveys
Other possible data sources
Specific population survey
Method of measurement
Analysis of country data on HIV prevalence, particularly among young age groups and, where available, direct HIV incidence data; internationally consistent modelled estimates, e.g. Spectrum AIM.
Method of estimation
Modelled estimates of the number of new HIV infections are produced and compiled by country teams and published annually by UNAIDS and WHO. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgment needs to be used as to the quality of the data and how representative it is of the population.
M&E Framework
Impact
Method of estimation of global and regional aggregates
Disaggregation
Age
Disaggregation
Sex
Unit of Measure
Cases
Unit Multiplier
Expected frequency of data dissemination
Annual
Expected frequency of data collection
Annual
Limitations
Links
Consolidated strategic information guidelines for HIV in the health sector (WHO, 2015)
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13432,14990,Estimated antiretroviral therapy coverage among children,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated antiretroviral therapy coverage among children\n\nName abbreviated\n\n \n\nData Type Representation\nPercent\n\nTopic\n\n \n\nISO Health Indicators Framework\nAccessibility\n\nRationale\n\n \n\nDefinition\nEstimated percentage of eligible children under the age of 15 currently receiving antiretroviral therapy\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nCalculating the numerator\n\nData for the calculation of the numerator are compiled from the most recent reports received by WHO, UNICEF and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services.\n \nEstimating the denominator\nThe Spectrum software package (WHO/UNAIDS) is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).\n \n \n \n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\n\n \n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:42:57,2018-03-23 12:42:57,2694,"Indicator name
Estimated antiretroviral therapy coverage among children
Name abbreviated
Data Type Representation
Percent
Topic
ISO Health Indicators Framework
Accessibility
Rationale
Definition
Estimated percentage of eligible children under the age of 15 currently receiving antiretroviral therapy
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Calculating the numerator
Data for the calculation of the numerator are compiled from the most recent reports received by WHO, UNICEF and/or UNAIDS from health ministries or from other reliable sources in the countries, such as bilateral partners, foundations and nongovernmental organizations that are major providers of treatment services.
Estimating the denominator
The Spectrum software package (WHO/UNAIDS) is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13430,14988,Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nEstimated number of people needing antiretroviral therapy\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\n\n \n\nRationale\nAs the HIV pandemic matures, increasing numbers of people are reaching advanced stages of HIV\ninfection. Antiretroviral therapy (ART) has been shown to reduce mortality amongst those infected and\nefforts are being made to make it more affordable within low- and middle-income countries.\n\nDefinition\nFor ADULTS: National HIV prevalence curves are used as a basis for calculating the numbers of people eligible for antiretroviral therapy. Several factors influence the number of adults eligible, including the CD4 count threshold at which antiretroviral\ntherapy is deemed necessary. In 2010, WHO recommended that the threshold be changed from 200 cells per mm3 to 350 cells per mm3\n– substantially increasing the number of people eligible for antiretroviral therapy in low- and middle-income countries.\nSpectrum (software developed by WHO/UNAIDS) tracks the number of adults living with HIV according to their CD4 count. This enables precise\nestimates of the numbers of adults who are eligible for antiretroviral therapy and of the number of people dying from AIDS-related causes.\nFor CHILDREN: The Spectrum software package is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nFor ADULTS: National HIV prevalence curves are used as a basis for calculating the numbers of people eligible for antiretroviral therapy. Several factors influence the number of adults eligible, including the CD4 count threshold at which antiretroviral\ntherapy is deemed necessary. In 2010, WHO recommended that the threshold be changed from 200 cells per mm3 to 350 cells per mm3\n– substantially increasing the number of people eligible for antiretroviral therapy in low- and middle-income countries.\nSpectrum (software developed by WHO/UNAIDS) tracks the number of adults living with HIV according to their CD4 count. This enables precise\nestimates of the numbers of adults who are eligible for antiretroviral therapy and of the number of people dying from AIDS-related causes.\nFor CHILDREN: the 2010 WHO treatment guidelines recommend that all children younger than 24 months living with HIV be provided with antiretroviral therapy regardless of CD4 counts.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nAge\n\nDisaggregation\nSex\n\nUnit of Measure\n\n \n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:42:56,2018-03-23 12:42:56,2694,"Indicator name
Estimated number of people needing antiretroviral therapy
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Rationale
As the HIV pandemic matures, increasing numbers of people are reaching advanced stages of HIV
infection. Antiretroviral therapy (ART) has been shown to reduce mortality amongst those infected and
efforts are being made to make it more affordable within low- and middle-income countries.
Definition
For ADULTS: National HIV prevalence curves are used as a basis for calculating the numbers of people eligible for antiretroviral therapy. Several factors influence the number of adults eligible, including the CD4 count threshold at which antiretroviral
therapy is deemed necessary. In 2010, WHO recommended that the threshold be changed from 200 cells per mm3 to 350 cells per mm3
– substantially increasing the number of people eligible for antiretroviral therapy in low- and middle-income countries.
Spectrum (software developed by WHO/UNAIDS) tracks the number of adults living with HIV according to their CD4 count. This enables precise
estimates of the numbers of adults who are eligible for antiretroviral therapy and of the number of people dying from AIDS-related causes.
For CHILDREN: The Spectrum software package is used to estimate the number of children up to the age of 15 living with HIV; the same estimate is used to identify the number of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the efficacy of various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s survival rates (depending, for example, on how and at what age they became infected).
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
For ADULTS: National HIV prevalence curves are used as a basis for calculating the numbers of people eligible for antiretroviral therapy. Several factors influence the number of adults eligible, including the CD4 count threshold at which antiretroviral
therapy is deemed necessary. In 2010, WHO recommended that the threshold be changed from 200 cells per mm3 to 350 cells per mm3
– substantially increasing the number of people eligible for antiretroviral therapy in low- and middle-income countries.
Spectrum (software developed by WHO/UNAIDS) tracks the number of adults living with HIV according to their CD4 count. This enables precise
estimates of the numbers of adults who are eligible for antiretroviral therapy and of the number of people dying from AIDS-related causes.
For CHILDREN: the 2010 WHO treatment guidelines recommend that all children younger than 24 months living with HIV be provided with antiretroviral therapy regardless of CD4 counts.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Age
Disaggregation
Sex
Unit of Measure
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)
13424,14982,Estimated number of people (all ages) living with HIV,"{""link"": ""http://apps.who.int/gho/data/node.home"", ""retrievedDate"": ""23-March-18"", ""additionalInfo"": ""Indicator name\nNumber of people living with HIV\n\nName abbreviated\n\n \n\nData Type Representation\nCount\n\nTopic\n\n \n\nISO Health Indicators Framework\nHealth conditions\n\nRationale\n\n \n\nDefinition\nThe number of people with HIV infection, whether or not they have developed symptoms of AIDS, estimated to be alive at the end of a specific year.\n\nAssociated terms\n\n \n\nPreferred data sources\n\n \n\nOther possible data sources\n\n \n\nMethod of measurement\n\n \n\nMethod of estimation\nCountries produce national estimates of the number of people living with HIV, which are compiled and published annually by UNAIDS and WHO. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgement needs to be used as to the quality of the data and how representative it is of the population.\n\nM&E Framework\n\n \n\nMethod of estimation of global and regional aggregates\n\n \n\nDisaggregation\nAge : 15+\n\nDisaggregation\nAge : <15\n\nDisaggregation\nSex : Female\n\nUnit of Measure\nPeople\n\nUnit Multiplier\n\n \n\nExpected frequency of data dissemination\n\n \n\nExpected frequency of data collection\n\n \n\nLimitations\n\n \n\nLinks\n\n \n\nComments\n\n \n\nContact Person\n\n \n\n"", ""dataPublishedBy"": ""World Health Organization Global Health Observatory (GHO)"", ""dataPublisherSource"": null}",2018-03-23 12:42:56,2018-03-23 12:42:56,2694,"Indicator name
Number of people living with HIV
Name abbreviated
Data Type Representation
Count
Topic
ISO Health Indicators Framework
Health conditions
Rationale
Definition
The number of people with HIV infection, whether or not they have developed symptoms of AIDS, estimated to be alive at the end of a specific year.
Associated terms
Preferred data sources
Other possible data sources
Method of measurement
Method of estimation
Countries produce national estimates of the number of people living with HIV, which are compiled and published annually by UNAIDS and WHO. Standard methods and tools for HIV estimates that are appropriate to the pattern of the HIV epidemic are used . However, to obtain the best possible estimates, judgement needs to be used as to the quality of the data and how representative it is of the population.
M&E Framework
Method of estimation of global and regional aggregates
Disaggregation
Age : 15+
Disaggregation
Age : <15
Disaggregation
Sex : Female
Unit of Measure
People
Unit Multiplier
Expected frequency of data dissemination
Expected frequency of data collection
Limitations
Links
Comments
Contact Person
",http://apps.who.int/gho/data/node.home,World Health Organization Global Health Observatory (GHO)